Value of an Integrated Home Dialysis Model in the United Kingdom: A Cost-Effectiveness Analysis

被引:5
作者
Erbe, Amanda W. [1 ,4 ]
Kendzia, Dana [2 ]
Busink, Ellen [2 ]
Carroll, Suzanne [3 ]
Aas, Eline [1 ]
机构
[1] Univ Oslo, Dept Hlth Management & Hlth Econ, Oslo, Norway
[2] Fresenius Med Care, Market Access & Hlth Econ, Bad Homburg, Germany
[3] Fresenius Med Care UK Ltd, Hlth Econ, Market Access & Prod Management, Huthwaite, England
[4] Univ Oslo, Dept Hlth Management & Hlth Econ, POB 1089 Blindern, Oslo 0317, Norway
关键词
economic evaluation; home hemodialysis; home -to -home transition; patient pathway management; peritoneal; dialysis; renal replacement therapy; QUALITY-OF-LIFE; PERITONEAL-DIALYSIS; HEMODIALYSIS; DISEASE; UTILITY; RISK;
D O I
10.1016/j.jval.2023.02.009
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objectives: This study aimed to determine the lifetime cost-effectiveness of increasing home hemodialysis as a treatment option for patients experiencing peritoneal dialysis technique failure compared with the current standard of care.Methods: A Markov model was developed to assess the lifetime costs, quality-adjusted life-years, and cost-effectiveness of increasing the usage an integrated home dialysis model compared with the current patient pathways in the United Kingdom. A secondary analysis was conducted including only the cost difference in treatments, minimizing the impact of the high cost of dialysis during life-years gained. Sensitivity and scenario analyses were performed, including analyses from a societal rather than a National Health Service perspective.Results: The base-case probabilistic analysis was associated with incremental costs of & POUND;3413 and a quality-adjusted life-year of 0.09, resulting in an incremental cost-effectiveness ratio of & POUND;36341. The secondary analysis found the integrated home dialysis model to be dominant. Conclusions on cost-effectiveness did not change under the societal perspective in eitherConclusions: The base-case analysis found that an integrated home dialysis model compared with current patient pathways is likely not cost-effective. These results were primarily driven by the high baseline costs of dialysis during life-years gained by patients receiving home hemodialysis. When excluding baseline dialysis-related treatment costs, the integrated home dialysis model was dominant. New strategies in kidney care patient pathway management should be explored because, under the assumption that dialysis should be funded, the results provide cost-effectiveness evidence for an integrated home dialysis model.
引用
收藏
页码:984 / 994
页数:11
相关论文
共 50 条
  • [41] Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore
    Yang, Fan
    Lau, Titus
    Luo, Nan
    NEPHROLOGY, 2016, 21 (08) : 669 - 677
  • [42] Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model
    Putri, Septiara
    Nugraha, Ryan R.
    Pujiyanti, Eka
    Thabrany, Hasbullah
    Hasnur, Hanifah
    Istanti, Novita D.
    Evasari, Diah
    Afiatin
    BMC RESEARCH NOTES, 2022, 15 (01)
  • [43] Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model
    Septiara Putri
    Ryan R. Nugraha
    Eka Pujiyanti
    Hasbullah Thabrany
    Hanifah Hasnur
    Novita D. Istanti
    Diah Evasari
    BMC Research Notes, 15
  • [44] Cost-effectiveness Analysis of Vascular Access Referral Policies in CKD
    Shechter, Steven M.
    Chandler, Talon
    Skandari, M. Reza
    Zalunardo, Nadia
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2017, 70 (03) : 368 - 376
  • [45] Efficacy and cost-effectiveness of home respiratory polygraphy
    Quiroga, Ma Angeles Sanchez
    Jimenez, Juan Fernando Masa
    Illa, Ferran Barbe
    Najera, Marta Cabello
    Oleo, Neus Salord
    Cantolla, Joaquin Duran
    Gil, Francisco Capote
    Mendez, Jesus Munoz
    Santos, Joaquin Teran
    Montserrat, Josep Maria
    Bravo, Monica De la Pena
    Serrano, Jose Carlos
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [46] Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa
    Thsehla, Evelyn
    Boachie, Micheal Kofi
    Goldstein, Susan
    BMC HEALTH SERVICES RESEARCH, 2025, 25 (01)
  • [47] Intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis: a cost-effectiveness analysis
    Ibrahim, Laila F.
    Huang, Li
    Hopper, Sandy M.
    Dalziel, Kim
    Babl, Franz E.
    Bryant, Penelope A.
    LANCET INFECTIOUS DISEASES, 2019, 19 (10) : 1101 - 1108
  • [48] Prevention of gram-positive infections in peritoneal dialysis patients in Hong Kong: A cost-effectiveness analysis
    Wong, Carlos
    Luk, In-wa
    Ip, Margaret
    You, Joyce H. S.
    AMERICAN JOURNAL OF INFECTION CONTROL, 2014, 42 (04) : 412 - 416
  • [49] Rapid cost-effectiveness analysis: hemodialysis versus peritoneal dialysis for patients with acute kidney injury in Rwanda
    Nemzoff, Cassandra
    Ahmed, Nurilign
    Olufiranye, Tolulope
    Igiraneza, Grace
    Kalisa, Ina
    Chadha, Sukrit
    Hakiba, Solange
    Rulisa, Alexis
    Riro, Matiko
    Chalkidou, Kalipso
    Ruiz, Francis
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2024, 22 (01)
  • [50] A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy
    Ingles, Jodie
    McGaughran, Julie
    Scuffham, Paul A.
    Atherton, John
    Semsarian, Christopher
    HEART, 2012, 98 (08) : 625 - 630